Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
收藏Figshare2025-11-26 更新2026-04-28 收录
下载链接：
https://figshare.com/articles/dataset/Table_3_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719268
下载链接
链接失效反馈官方服务：
资源简介：
TRAEs (reported as PTs) in ≥20% of patients, grade ≥3 TRAEs in ≥5% of patients, and AESIs in ≥10% of patients in the dose-expansion phase.
创建时间：
2025-11-26
